| Issue Date |
Title |
Author(s) |
| 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia |
Huang, Xinfang;Du, Hui;Gu, Jieruo;Zhao, Dongbao;Jiang, Lindi;Li, Xinfu;Zuo, Xiaoxia;Liu, Yi;Li, Zhanguo;Li, Xiangpei;Zhu, Ping;Li, Juan;Zhang, Zhiyi;Huang, Anbin;Zhang, Yuanchao;Bao, Chunde |
| Jun-2020 |
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial |
Su, Jinmei;Li, Mengtao;He, Lan;Zhao, Dongbao;Wan, Weiguo;Liu, Yi;Xu, Jianhua;Xu, Jian;Liu, Huaxiang;Jiang, Lindi;Wu, Huaxiang;Zuo, Xiaoxia;Huang, Cibo;Liu, Xiumei;Li, Fen;Zhang, Zhiyi;Liu, Xiangyuan;Dong, Lingli;Li, Tianwang;Chen, Haiying;Li, Jingyang;He, Dongyi;Lu, Xin;Huang, Anbin;Tao, Yi;Wang, Yanyan;Zhang, Zhuoli;Wei, Wei;Li, Xiaofeng;Zeng, Xiaofeng |
| 2015 |
Feasibility and Influential Factors in Performing Self-Evaluation of DAS28 with Smart System of Disease Management (SSDM) By RA Patient in China |
Rong, Mu;Xiao, Fei;Li, Chun;Guan, Jianlong;Shen, Yan;Zhao, Dongbao;Xu, Xia;Jiang, Lindi;Chen, Huiyong;Su, Li;Jia, Yuhua;Zhang, Li;Liu, Yuan;Li, Zhan-Guo |
| 2014 |
Novel Risk Loci for Rheumatoid Arthritis in Han Chinese and Congruence With Risk Variants in Europeans |
Jiang, Lei;Yin, Jian;Ye, Lingying;Yang, Jian;Hemani, Gibran;Liu, Ai-Jun;Zou, Hejian;He, Dongyi;Sun, Lingyun;Zeng, Xiaofeng;Li, Zhanguo;Zheng, Yi;Lin, Yiping;Liu, Yi;Fang, Yongfei;Xu, Jianhua;Li, Yinong;Dai, Shengming;Guan, Jianlong;Jiang, Lindi;Wei, Qianghua;Wang, Yi;Li, Yang;Huang, Cibo;Zuo, Xiaoxia;Liu, Yu;Wu, Xin;Zhang, Libin;Zhou, Ling;Zhang, Qing;Li, Ting;Chen, Ling;Xu, Zhen;Yang, Xiaoping;Qian, Feng;Xie, Weilin;Liu, Wei;Guo, Qian;Huang, Shaolan;Zhao, Jing;Li, Mengmeng;Jin, Yanhua;Gao, Jie;Lv, Ying;Wan |
